Literature DB >> 10667730

Development of an antithrombogenic and antitraumatic blood pump: the Gyro C1E3.

T Takano1, K Nakata, M Yoshikawa, T Maeda, J Glueck, A Fujisawa, K Makinouchi, M Yokokawa, S Murabayashi, Y Nosé.   

Abstract

The Gyro C1E3 is a centrifugal blood pump. Its antithrombogenic and antitraumatic blood features were demonstrated by prior studies. Based upon these studies, a mass production model of the C1E3 is becoming commercially available. Therefore, this feasibility study was conducted using the mass production models of the Gyro C1E3 for long-term cardiac assist in ex vivo animal experiments. Five healthy calves were used and 15 pump heads were applied for different time periods (Group 1, 30 days; Group 2, 14 days; Group 3, 10 and 7 days; Group 4, 4 days; and Group 5, 2 days). Activated clotting time (ACT) was kept at 200-250 sec. All five calves demonstrated neither abnormal signs nor abnormal blood examination data throughout the experiment. During necropsy, no thromboembolism was found in any downstream organs. Groups 1-4 showed thrombi inside the pump heads while two pumps in Group 5 had no thrombi formations. Bearing deformation or possible wear did not increase after 2 days of pumping. The C1E3 is capable of long-term assist circulation. However, after 2 days of pumping, careful observation is necessary since thrombi may occur inside the pump when ACT is controlled under 250 sec. During the weaning stage or low flow (under 2 L/min), over 250 sec of ACT is recommended to assure the safety of the patient.

Entities:  

Mesh:

Year:  2000        PMID: 10667730     DOI: 10.1097/00002480-200001000-00028

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  1 in total

1.  Biventricular support using a centrifugal pump in a 6 year old with fulminant myocarditis.

Authors:  Hiromu Kehara; Tamaki Takano; Takamitsu Terasaki; Kenji Okada
Journal:  J Artif Organs       Date:  2016-12-01       Impact factor: 1.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.